[PDF] Top 20 Anaya MATEMÁTICAS 4º Evaluación
Has 10000 "Anaya MATEMÁTICAS 4º Evaluación" found on our website. Below are the top 20 most common "Anaya MATEMÁTICAS 4º Evaluación".
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
... Our meta-analysis also provides an overview of the expected safety and tolerance of single-agent PARPi that can be of value to discuss treatment risk and benefit ratio with ... See full document
212
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis
... Despite these encouraging results, many unsolved questions remain regarding targeted therapies combined with CT in TNBC patients. There are still no answers for some important points: which is the most suitable ... See full document
18
Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis
... AIs treatment were ex- tracted from the safety profiles of included trials to calculate CVEs ...of patients developed ...data analysis when heterogeneity ...[30–32]. Meta-Analyses (PRISMA) ... See full document
112
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
... This systematic review of the literature revealed associa- tions between CYP19A1 polymorphisms and clinical outcomes and AEs in BC patients receiving ...on treatment with AIs in ...BC ... See full document
50
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
... a systematic search in PubMed EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), up to April 2018, to identify phase III, RCTs comparing ICIs (anti- CTLA-4, anti-PD1, or anti-PD-L1) versus ... See full document
96
Review Article A systematic review and meta-analysis of comparative studies on the efficacy of cytoreductive prostatectomy in patients with metastatic prostate cancer
... high-risk patients with PCa are those likely to benefit fr- om multi disciplinary interven- tions as they are more likely to have biochemical recurrence after initial treatment ...[32]. Patients with ... See full document
5
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
... Since BRCA- mutated tumours represent up to 25% of all TNBC [19], it would be important to establish predict- ive factors that allow for patient selection for platinum- based ...treatment. ... See full document
6
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
... for patients with small tumors (< 2 cm) show a slightly greater OS advantage was provided by H/anthra- cycline-containing chemotherapy compared with H/ non-anthracycline-containing ...Central Cancer ... See full document
5
The benefit of HER2 targeted therapies on overall survival of patients with metastatic HER2 positive breast cancer – a systematic review
... of HER2 com- bination therapies have been evaluated in RCTs, as it was noted in a previous meta-analysis (Harris et ...anti-HER2 agent to a given cytotoxic or combination of cytotoxic ... See full document
14
mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
... positive HER2-negative advanced disease recurred or progressed after treatment with letrozole or anastrozole ...(485 patients) versus 3.2 months in control arm (239 patients) (HR: ... See full document
58
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
... (HER2) negative metastatic breast cancer (BC) accounts for 73% of ...molecular analysis of this disease is essential for potential options for targeted ...angiogenesis ... See full document
220
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
... Estimates of PFS and overall survival (OS) were from Kaplan–Meier curves and tests of differences by log-rank test. Univariable and multivariable Cox-regression analyses were used to test the independent prognostic ... See full document
126
Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
... for HER2-positive disease, which accounts for 20% of all breast cancer ...and HER2 status. Although HER2-positive patients exhibit higher risk for recurrence or disease progres- ... See full document
14
Prospects for combining immune checkpoint blockade with PARP inhibition
... anti-CTLA-4 treatment in BRCA1 deficient ovarian can- cer model ...combination treatment completely eliminated visible tumor mass and maintained a long-term tumor- free survival in most of mice ... See full document
79
Profile of veliparib and its potential in the treatment of solid tumors
... the PARP inhibitors now in clinical trials have shown some preclinical differences, especially in the degree of PARP trapping, the true clinical significance of these differences is not yet ...robust ... See full document
8
Original Article Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells
... After treatment, survival curves were obtained and radiosensitivity parameters were calculat- ed using the multi-target single-hit ...of BRCA mutant breast cancer is higher than that of ... See full document
23
Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
... to HER2 therapy reinitiation or death was 51 months (range 5–124 months) in connec- tion with the longest HER2 therapy discontinuation period (figure ...(42.9%) patients had received hormonal therapy ... See full document
71
Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report
... that patients become resistant to ...best treatment choice for patients with LM (and Eastern Cooperative Oncology Group scores of 0–2) carrying the EGFR mutation ... See full document
14
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
... treat patients whose HR-positive HER2-negative breast cancer had progressed on prior endocrine therapy confirmed the generally favorable safety profile that was also observed when ... See full document
39
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2 Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
... second-line treatment and supported and informed the development of the phase 3 RESILIENCE study ...in patients with advanced breast ...and treatment of ...symptomatic treatment ... See full document
6
Related subjects